Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 19/20 | 0.87 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.59 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.59 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.59 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.59 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.59 |
| ▸ | BCR | P11274 | 1/20 | 0.57 |
| ▸ | KIT | P10721 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL588662 | 0.93 | ABL1 (1.00) | ABL1DDR1NTRK1NTRK3NTRK2 | |
| SCHEMBL589428 | 0.93 | ABL1 (0.86) | ABL1DDR1NTRK1NTRK3NTRK2 | |
| Hydrochloric Acid SCHEMBL31734730 | 0.92 | ABL1 (0.85) | ABL1DDR1NTRK1NTRK3NTRK2 | |
| SCHEMBL15511376 | 0.91 | ABL1 (0.77) | ABL1BCR | |
| SCHEMBL9610977 | 0.88 | ABL1 (1.00) | ABL1 | |
| SCHEMBL30010196 | 0.88 | ABL1 (1.00) | ABL1 | |
| SCHEMBL9610965 | 0.87 | ABL1 (1.00) | ABL1DDR1NTRK1NTRK3NTRK2 | |
| SCHEMBL4121584 | 0.86 | ABL1 (0.73) | ABL1BCR | |
| SCHEMBL589960 | 0.86 | ABL1 (1.00) | ABL1DDR1NTRK1NTRK3NTRK2 | |
| SCHEMBL15061695 | 0.86 | ABL1 (0.88) | ABL1DDR1NTRK1NTRK3NTRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140066434-A1 | Methods and Compositions for Treating Parkinson's Disease | ARIAD PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | claimed |
| US-20140066434-A1 | Methods and Compositions for Treating Parkinson's Disease | ARIAD PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066434-A1 | Methods and Compositions for Treating Parkinson's Disease | PARK7, SNCA, HTT | ABL1 2649/4885DDR1 4848/4885NTRK1 4165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.